Allergy and immunology practices are among the most administratively intensive in outpatient medicine. A mid-sized allergy practice may be managing hundreds of patients on active allergen immunotherapy—each requiring regular injection appointments, vial maintenance, and insurance coordination—alongside a growing population of patients receiving biologic therapies for severe asthma and allergic conditions. Virtual assistants trained in this environment are not a luxury; they are a functional necessity for practices that want to grow without administrative chaos.
The Scale of Immunotherapy Management
The American Academy of Allergy, Asthma and Immunology estimates that approximately 5 to 8 percent of the U.S. population has food allergy, and tens of millions more suffer from allergic rhinitis, asthma, and other conditions that benefit from allergen immunotherapy. Subcutaneous immunotherapy—allergy shots—requires patients to come in for injections on a schedule that begins weekly and transitions to monthly maintenance visits over three to five years.
A single allergist with 300 active immunotherapy patients is managing a continuous flow of injection appointments, vial preparation coordination, dosing record maintenance, and reaction documentation. When that patient volume is layered on top of new patient consultations, skin testing appointments, and spirometry assessments, the scheduling complexity becomes one of the primary operational constraints on practice growth.
Injection Scheduling and Vial Lifecycle Management
Virtual assistants for allergy practices take ownership of the injection appointment calendar—ensuring that every patient is scheduled within the interval window specified by their dosing protocol, sending appointment reminders, and managing the waitlist when openings occur. For practices offering build-up scheduling flexibility to accommodate patient schedules, the VA manages the dosing interval calendar so that no patient inadvertently exceeds their safe interval and requires a dosing step-back.
Vial management is an equally important VA function. Each patient's custom allergen vial has a preparation date, a 90-day discard-after date (or similar expiration per practice protocol), and a series of dose vials moving from concentrate to maintenance. VAs track vial expiration dates across the active patient panel, alert the clinic when vials are approaching expiration, and coordinate vial renewal orders with the allergen preparation center or in-house pharmacy.
This vial tracking function prevents the scenario where a patient arrives for a scheduled injection only to find their vial has expired—an outcome that disrupts care, damages patient trust, and requires a partial or full dosing restart.
Biologic Therapy Prior Authorization
The last decade has seen a significant expansion of FDA-approved biologic therapies in allergy and immunology: dupilumab for atopic dermatitis and asthma, omalizumab for allergic asthma and chronic urticaria, mepolizumab and benralizumab for severe eosinophilic asthma, and an expanding pipeline of newer agents. These medications are expensive—often $15,000 to $30,000 per year or more—and every course of treatment requires prior authorization, step therapy documentation, and often multiple appeal cycles.
A 2023 survey by the American Medical Association found that 93 percent of physicians reported prior authorization delays negatively impacting patient care. In allergy and immunology, where biologic therapy is often the difference between controlled and uncontrolled severe asthma, authorization delays carry genuine clinical stakes.
VAs trained in biologic prior authorization build the authorization submission package—clinical notes documenting disease severity, prior treatment failure, biomarker results where required, and the specific carrier's clinical criteria checklist—and submit through the appropriate portal. They track the decision timeline, initiate appeals when denied, and follow the case through to approval. This function, systematically executed, reduces the time patients wait for access to approved therapies.
Patient Communication in a Long-Term Treatment Model
Immunotherapy patients are among the most loyal in medicine—a successful allergy practice builds a patient relationship that spans three to five years of active treatment and a lifetime of follow-up care. But maintaining that relationship requires consistent communication that keeps patients engaged through the often-slow improvement of immunotherapy and informed about changes in their treatment protocol.
VAs manage patient communication at every stage: onboarding new immunotherapy patients with protocol education, sending milestone acknowledgments as patients progress through build-up, communicating dosing adjustments after reactions, and executing the annual reassessment outreach that prompts patients to return for allergen retesting and protocol review.
Allergy and immunology practices ready to scale their administrative infrastructure should explore the trained virtual assistants at Stealth Agents, where teams experienced in high-volume injection program management, biologic authorization, and immunology patient communication are available on flexible engagement terms.
The Revenue Impact of Administrative Precision
An allergy practice that keeps its immunotherapy patients on schedule, manages its vial expirations proactively, and moves its biologic authorization requests through the approval process efficiently is a practice that maximizes revenue from every patient relationship. VAs do not generate this precision occasionally—they generate it systematically, across the entire patient panel, every day.
For practices that have been limited in growth by administrative bandwidth, the deployment of trained VAs often represents the single highest-ROI staffing decision available.
Sources
- American Academy of Allergy, Asthma and Immunology, Allergy Statistics and Immunotherapy Overview
- American Medical Association, 2023 Prior Authorization Physician Survey
- Journal of Allergy and Clinical Immunology, Biologic Therapies in Severe Asthma: Access and Adherence